Targeted Biome Bacteriolysis™: A New Antimicrobial Approach

Targeted Biome Bacteriolysis™ occurs when an endolysin peptidoglycan hydrolase effectively targets specific pathogenic bacteria while sparing unintended targets. This technology leverages the action of a bacteriophage to create an engineered endolysin.

In Nature

  • Stage 1

    In nature, phage DNA enters bacterial cells at local activity of virion-associated cell wall hydrolases.

  • Stage 2

    Once inside the cell wall, new phages are released from the infected host cell, creating soluble lytic enzymes. These endolysins lyse the cell wall, targeting essential bacterial structure and ultimately resulting in bacterial death.

Topical Engineered Endolysins

  • Stage 1

    Copying what our body does naturally, Micreobalance® is the first engineered endolysin peptidoglycan hydrolase that can effectively target specific bacteria of the microbiome while sparing unintended targets.

  • Stage 2

    Working from the outside in, topically applied endolysins lyse the bacterial cell wall. By targeting the bad and protecting the good, topically applied endolysins balance the skin microbiome.

Introducing GladskinMD

GladskinMD offers medical strength, biome therapeutic skincare with Micreobalance®, our patented endolysin technology that addresses skin microbiome health head-on. Our products are formulated for atopic dermatitis patients seeking medical care for their skin. Gladskin MD is available exclusively through healthcare providers.

Discover our MD Line

The GladskinMD range of products is formulated specifically to meet the needs of patients who are seeking care for their atopic dermatitis through a licensed healthcare provider.

GladskinMD is only sold through healthcare providers.

Sign-up to learn more
"Endolysin science is compelling as a novel approach to addressing dysbiosis in AD. I’m excited about GladskinMD’s work in this space."
-Dr. Peter Lio, MD, FAAD
Clinical Assistant Professor of Dermatology & Pediatrics, Northwestern University Feinberg School of Medicine
Founding Director, Chicago Integrative Eczema Center
Learn about biome therapeutics

Temporal Shifts in The Skin Microbiome Associated with
Disease Flares and Treatment In Children with Atopic Dermatitis¹

A Skin Microbiome Balancing Act

Healthy skin requires a healthy microbiome. But eczematous skin is often in dysbiosis: an estimated 80% of atopic dermatitis patients are overcolonized with S. aureus, a pathogenic bacteria that drives eczema flares. ², ³

Overcolonization is a moving target: it can occur on certain areas of the body but not others and recur over time. Addressing persistent microbiome dysbiosis is critical to restoring AD patients’ skin health.

Generational Skincare Inspired by Real People

AD patients’ skincare needs evolve as they progress through life. We are committed to creating products that improve people’s lives across generations.

Learn More

Living Fully While Managing AD

Atopic dermatitis has a profound impact on quality of life. We believe skincare should help patients address eczema’s ramifications so they can lead fuller, more comfortable lives.

Learn More About Our Products

This primary symptom of AD is highly disruptive and impacts patients’ social, emotional, and professional lives.

Chronic Itch

Adults and children with AD experience disrupted sleep⁴ that can lead to poorer health outcomes.⁵ Their caregivers aren’t sleeping well either. ⁶, ⁷

Sleep Disturbance

This seldom acknowledged AD symptom can be debilitating and difficult to manage.

Skin Pain

Itching attacks and uncomfortable skin can impact focus and make it hard to succeed at–or even attend–work or school.

School & Work Disruptions

People with AD have higher rates of anxiety and depression ⁸ and are 44% more likely to exhibit suicidal ideation.⁹

Mental Health

AD is a visible marker of difference that can impact patients’ confidence, sense of self and relationships with others.

Self Esteem & Relationships

Our Formulations

We partner with leading researchers and dermatologists to develop products optimized for patients living with atopic dermatitis. All of our ingredients are intentionally selected to promote skin health.

  • Micreobalance®

    Our proprietary endolysin that targets pathogenic bacteria, including antibiotic resistant strains.

  • Ethyl Macadamiate

    An essential fatty acid derived from macadamia nut oil that prevents moisture loss. Allergy-safe: no nut protein present.

  • Jojoba Esters

    A non-greasy emollient derived from jojoba that acts as an anti-inflammatory skin conditioner. Superior stability.

  • Glycerol

    A hydrating trihydroxy alcohol that supports skin elasticity and barrier repair.
See our collection

About Us

Gladskin & GladskinMD are on a mission to improve quality of life for millions of people living with inflammatory skin conditions worldwide.

Our revolutionary non-prescription products for atopic dermatitis use patented endolysin science to balance the skin microbiome and restore skin health. GladskinMD is a subsidiary of the Dutch & Swiss biotechnology company Micreos Holdings, which is developing sustainable alternatives to antibiotics.

Citations

1

1: Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, Nomicos E, Polley EC, Komarow HD; NISC Comparative Sequence Program; Murray PR, Turner ML, Segre JA. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012 May;22(5):850-9. doi: 10.1101/gr.131029.111. Epub 2012 Feb 6. PMID: 22310478; PMCID: PMC3337431.

2

2: Kim JE, Kim HS. Microbiome of the Skin and Gut in Atopic Dermatitis (AD): Understanding the Pathophysiology and Finding Novel Management Strategies. J Clin Med. 2019 Apr 2;8(4):444. doi: 10.3390/jcm8040444. PMID: 30987008; PMCID: PMC6518061.

3

3: Higaki, S., Morohashi, M., Yamagishi, T., & Hasegawa, Y. (1999). Comparative study of staphylococci from the skin of atopic dermatitis patients and from healthy subjects. International journal of dermatology, 38(4), 265–269. https://doi.org/10.1046/j.1365-4362.1999.00686.

4

4:  Ramirez FD, Chen S, Langan SM, et al. Association of Atopic Dermatitis With Sleep Quality in Children. JAMA Pediatr. 2019;173(5):e190025. doi:10.1001/jamapediatrics.2019.0025

5

5: Jonathan I. Silverberg, Nitin K. Garg, Amy S. Paller, Anna B. Fishbein, Phyllis C. Zee,

Sleep Disturbances in Adults with Eczema Are Associated with Impaired Overall Health: A US Population-Based Study, Journal of Investigative Dermatology, Volume 135, Issue 1, 2015, Pages 56-66, ISSN 0022-202X, https://doi.org/10.1038/jid.2014.325. (https://www.sciencedirect.com/science/article/pii/S0022202X15370469).

6

6: McCleary KK. More Than Skin Deep: Understanding the Lived Experience of Eczema. Paper presented at: Eczema Patient-Focused Drug Development Meeting; March, 2020, 2019.

7

7: Angelhoff C, Askenteg H, Wikner U, Edell-Gustafsson U. “To Cope with Everyday Life, I Need to Sleep” – A Phenomenographic Study Exploring Sleep Loss in Parents of Children with Atopic Dermatitis. J Pediatr Nurs. 2018;43:e59-e65.

8

8: Schonmann Y, Mansfield KE, Hayes JF, Abuabara K, Roberts A, Smeeth L, Langan SM. Atopic Eczema in Adulthood and Risk of Depression and Anxiety: A Population-Based Cohort Study. J Allergy Clin Immunol Pract. 2020 Jan;8(1):248-257.e16. doi: 10.1016/j.jaip.2019.08.030. Epub 2019 Aug 31. PMID: 31479767; PMCID: PMC6947493.

9

9: Sandhu, J. K., Wu, K. K., Bui, T. L., & Armstrong, A. W. (2019). Association Between Atopic Dermatitis and Suicidality: A Systematic Review and Meta-analysis. JAMA dermatology, 155(2), 178–187. https://doi.org/10.1001/jamadermatol.2018.4566